Yoshitaka Inoue

Dr. Yoshitaka Inoue

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2018 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
YIYoshitaka Inoue
Yoshitaka Inoue
SEShinya Endo
Shinya Endo
NMNaofumi Matsuno
Naofumi Matsuno
YKYoshitaka Kikukawa
Yoshitaka Kikukawa
TSTakafumi Shichijo
Takafumi Shichijo
MMMasao Matsuoka
Masao Matsuoka

1 December 2004 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Closed access
PDF file
YIYoshitaka Inoue
Yoshitaka Inoue

31 August 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
YIYoshitaka Inoue
Yoshitaka Inoue
NNNobuaki Nakano
Nobuaki Nakano
SFShigeo Fuji
Shigeo Fuji
TETetsuya Eto
Tetsuya Eto
TKToshiro Kawakita
Toshiro Kawakita
ATATL Working Group of the Japan Society for Hematopoietic Cell Transplantation
ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation

19 April 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
YIYoshitaka Inoue
Yoshitaka Inoue
KOKeiji Okinaka
Keiji Okinaka
SFShigeo Fuji
Shigeo Fuji
YIYOSHIHIRO INAMOTO
YOSHIHIRO INAMOTO
NUNaoyuki Uchida
Naoyuki Uchida
TTTransplant Complications Working Group of The Japan Society for Hematopoietic Cell Transplantation
Transplant Complications Working Group of The Japan Society for Hematopoietic Cell Transplantation

27 October 2021 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
YIYoshitaka Inoue
Yoshitaka Inoue
NNNao Nishimura
Nao Nishimura
MMMasayuki Murai
Masayuki Murai
MMMiho Matsumoto
Miho Matsumoto
MWMiho Watanabe
Miho Watanabe
MMMasao Matsuoka
Masao Matsuoka

10 April 2025 in Cells
Verified
Journal Article
Open access
PDF file
YIYoshitaka Inoue
Yoshitaka Inoue
JCJoseph Cioccio
Joseph Cioccio
SMShin Mineishi
Shin Mineishi
KMKentaro Minagawa
Kentaro Minagawa
In recent years, treatments in the field of hematologic malignancies have undergone significant evolution; allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shifted from an “ultimate” therapy to becoming a component of a comprehensive therapeutic strategy for acute myeloid leukemia (AML). Advances in risk stratification (including molecular profiling and measurable residual disease assessment), conditioning regimens, and graft-versus-host disease (GVHD) prophylaxis—such as post-transplant cyclophosphamide—have improved outcomes and expanded donor selection and transplant eligibility. We should not only focus on the transplantation procedure but also consider various therapeutic components, including chemotherapy, targeted therapy (possibly including chimeric antigen receptor T-cell therapy), and post-transplant maintenance therapy, which need to be orchestrated within the broader context of leukemia treatment. In this review, we summarized key developments in allo-HSCT for AML and aim to “decipher” each component of transplantation.